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Abstract
Introduction The aim of the study was to perform a comparative
analysis of LOH (loss of heterozygosity) in primary tumors as
well as peripheral blood and bone marrow (BM) of patients with
breast cancer (BCa).
Methods Performing PCR-based fluorescence microsatellite
analysis and using a panel of seven polymorphic microsatellite
markers, we compared the profiles of LOH in primary tumors,
peripheral blood and BM plasma from patients with primary BCa
(n = 40, stage M0) as well as tumor tissues and blood serum
from metastatic BCa patients (n = 48, stage M1). During the
course of systemic treatment blood samplings from 12 M0 and
16 M1 patients were at least once repeated.
Results The overall incidences of LOH in tumor tissues, blood
and BM samples were 27.5%, 9.0% and 5.0%, respectively.
The marker D3S1255 was the only one in the panel that showed
similar frequencies of LOH ranging from 19.0 to 24.5% in tumor,
blood and BM samples. Both M0 blood serum and BM plasma
samples displayed the same rate of 19.0%, whereas tumor and
M1 serum showed a rate of 24.5% and 24.0%, respectively, at
this locus. This marker also showed the highest frequency of
LOH in serum and BM samples, whereas in tumor samples
LOHs at the markers D13S218 (38%) and D17S855 (36%)
were more frequent. Statistical analysis of the tumor samples
showed that occurrence of LOH at the markers D3S1255
(P < 0.04), D9S171 (P  < 0.05) and D17S855 (P  < 0.03)
correlated with undifferentiated nuclear grade. Additionally,
significant associations of the number of LOH recorded at
D17S250 with estrogen receptor (P  < 0.02), progesterone
receptor (P < 0.03) expression and high proliferation score (Ki-
67 expression, P  = 0.009) were observed. In blood serum
samples a relationship between positive lymph node status and
LOH at the marker D3S1255 was revealed (M0 stage, P = 0.05;
M0+M1 stage, P = 0.004).
Conclusion Our study demonstrates heterogeneous profiles
and low rates of LOH, particularly on free DNA in BM and blood
samples. However, the significant associations of LOH with
some risk factors and the demonstrated possibility of monitoring
free DNA in patients undergoing systemic therapy suggest that
LOH analysis may be developed into a useful diagnostic tool.
Introduction
Breast cancer (BCa) is the most frequent malignant cancer of
women western industrial nations. One in ten women will
develop BCa.
With the use of traditional prognostic factors, it has still not
been possible to reliably identify those patients with BCa who
will relapse with metastatic disease. Therefore, improved
approaches should be developed to identify additional factors
that enable individual risk assessment. Besides the classical
factors being engaged in differentiation status, histological
type, angio-invasion, steroid hormone receptor status, as well
as the involvement of lymph nodes and age of patients with
breast cancer, new prognostic and predictive factors are
used. They reflect the morphological and molecular character-
istics of tumors, such as S-phase-fraction, Ki-67, epidermal
growth factor receptor (EGFR), HER2  oncogene, invasion
and metastasis markers like tumor-associated proteases and
associated inhibitors, and measurement of vessel density for
the assessment of angiogenesis [1]. However, despite this
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multifactoral prognostic model and advances in the treatment
of BCa, comprehensive knowledge of the genetic bases and
biological consequences is also required. In addition, the
established prognostic factors are determined in primary
tumors that are routinely removed by surgery. Therefore, the
development of blood or bone marrow (BM) tests with clinical
relevance for risk estimation and measurement of residual
tumor load is of great interest [2,3].
The carcinogenesis of breast cancer is a complex multistep
process associated with numerous genetic alterations and an
early hematogeneous dissemination of tumor cells [2-4]. DNA
alterations and downregulation of tumor-suppressor genes,
such as genes that encode molecules involved in cell adhe-
sion, cell-cycle arrest and apoptosis, are associated with BCa
[5]. Experimental studies introducing chromosomal DNA with
deleted regions into cell lines have demonstrated that tumor
growth and disease progression of BCa was promoted by
such an introduction. The systematic use of microcell hybrid
clones has identified a number of chromosomal regions that
are important for the proliferation of breast tumor cells [6,7].
With different methods, such as microsatellite analyses and
CGH (comparative genomic hybridization), a number of puta-
tive tumor-suppressor genes can be characterized [8-11].
Presence of allelic imbalance at definite chromosomal regions
is sufficient to provide selective growth advantage of BCa
cells. However, the number of known candidate genes that
have a role in the development of BCa is still limited [12].
Among these genes, the recently identified tumor-suppressor
genes BRCA1 and BRCA2 contribute to a substantial portion
of inherited BCa [13]. During progression of BCa a potential
relationship between specific genetic alterations at the locus
17q21 and hormonal deregulation has been observed [14].
Genetic aberrations that affect chromosome arms 7p, 16q,
17p and 17q seem to be early events [11]. LOH at region
16q22.2-q23.2 seems to be a major event in the genesis of
metastases [15].
During tumorigenesis free DNA may be released early from
apoptotic or necrotic cells into the blood circulation [16-18].
In the blood of patients with prostate cancer we detected
increased concentrations of extracellular DNA [19]. Further-
more, allelic imbalance could be identified in the serum or
plasma of patients with various tumor types [20-27]. Blood
may therefore be a convenient source for the detection of such
tumor-associated DNA abnormalities. It constitutes a pool of
free DNA derived from different sources, amongst others from
heterogenous areas of the primary tumor. A further important
feature is the possibility of taking repeated blood samples dur-
ing treatment.
Using PCR-based microsatellite analysis, our study demon-
strates heterogeneous distribution of LOH in primary tumor,
serum and BM of BCa patients and significant associations
with established risk factors. To our knowledge, this is the first
study to compare the presence and validity of LOH in different
tissue compartments.
Materials and methods
Patients and samples
Blood serum of BCa patients with primary breast cancer (n =
40, stage M0) was taken after surgery before the initiation of
adjuvant therapy. Blood serum of patients with metastatic dis-
ease (n = 48, stage M1) was collected 1 to 11 years after sur-
gery of the primary tumor. Of 28 patients (n = 12 M0, n = 16
M1), repeated blood collections during the course of treat-
ment were included. In addition, primary tumors and BM aspi-
rates were available from 60 (n = 30 M0, n = 30 M1) and 22
patients (n = 22 M0), respectively. Blood samples were taken
between February 2002 and October 2003 from patients who
received systemic therapy at the outpatient clinic of the
department of gynecology and who agreed to participate in
this study.
Patients treated for primary BCa underwent surgery including
lumpectomy and dissection of axillary lymph nodes or modified
radical mastectomy. All patients had epithelial BCa, and meta-
static spread was excluded by chest radiology, liver ultrasound
scan and bone scan. These patients received adjuvant treat-
ment (endocrine treatment and/or anthracycline-containing
chemotherapy as well as radiotherapy) according to national
guidelines.
Patients with metastatic disease received chemotherapy,
endocrine treatment, or treatment with the humanized anti-
HER2 antibody Trastuzumab (Herceptin) alone or in combina-
tion with chemotherapy.
The median age of M0 and M1 patients was 58 (range 29 to
77) and 59 (range 31 to 83) years, respectively.
All patients gave their informed consent and the examination
of the clinical material was approved by the local ethics review
board.
Immunohistochemistry and DNA preparation from 
paraffin-embedded tissues
Sections of 5 μm thickness were cut from formalin-fixed, par-
affin-embedded breast tumor blocks and mounted on micro-
scope slides.
Paraffin-embedded sections of the primary tumors were
stained for the expression of HER2 (antibody CB 11; Novo-
castra, Newcastle upon Tyne, UK), estrogen receptor (anti-
body NCL-6F11, Novocastra), progesterone receptor
(antibody NCL-PGR-312, Novocastra) and the proliferation
antigen Ki-67 (clone MIB-1; Dako, Hamburg, Germany). Stain-
ing for HER2 was expressed as 'DAKO-Score' with values
between 0 and 3+ (only 3+ was considered as positive); stain-Available online http://breast-cancer-research.com/content/9/5/R66
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ing for estrogen and progesterone receptors was evaluated
according to the system of Remmele and Stegner [28], and a
score greater 1 was regarded as positive. Proliferation was
evaluated as the percentage of cells stained positive with the
antibody MIB-1.
For microscopic evaluation the paraffin slices were stained
with haematoxylin and eosin (Merck, Darmstadt, Germany).
The tumor tissue of paraffin slices were either scraped off from
H/E-stained slides under a microscope or computer-assisted
microdissected from unstained slides via laser pressure
catapultation.
Preparation of serum and leukocytes
Approximately 10 ml blood were drawn by vein puncture and
centrifuged at 2,500 g for 10 min. The upper phase contained
the blood serum, from which 2 to 3 ml was removed for the
extraction and analysis of the circulating DNA. The remaining
17 to 18 ml blood were supplemented up to 50 ml with lysis
buffer containing 0.3 M sucrose, 10 mM Tris-HCl pH 7.5, 5
mM MgCl2 and 1% Triton ×100 (Sigma, Taufkirchen, Ger-
many). Following incubation for 15 min on ice, the isolation
and purification of the leukocytes were carried out by two cen-
trifugation steps at 2500 g, 4°C for 20 min.
Preparation of bone marrow specimens
BM specimens obtained in parallel with the blood samples
were aspirated directly after surgery under general anaesthe-
sia from both iliac crests and stored in heparinized tubes with
DMEM (Gibco, Eggenstein, Germany). After centrifugation at
400  g  for 5 min the supernatant containing the cell-free
plasma for further analysis of circulating DNA was removed.
DNA extraction and fluorencence-labeled PCR
Genomic DNA was extracted from microdissected tumor tis-
sues, blood serum, BM plasma and leukocytes (reference
DNA) of each patient using the QIAamp DNA Mini Kit and a
vacuum chamber (Qiagen QIAvac24) according to the manu-
facturer instructions (Qiagen, Hilden, Germany). Quantifica-
tions and qualities of the isolated DNA were
spectrophotometrically determined at 260 and 280 nm,
respectively (Eppendorf, Hamburg, Germany). Dilution experi-
ments to determine the lowest portion of tumor-specific DNA
that could be detected were performed. For this study we
mixed and amplified known quantities and proportions of nor-
mal (leukocyte) DNA and tumor or plasma DNA.
10 ng of DNA samples were amplified in a 10-μl reaction vol-
ume containing PCR Gold buffer (150 mM Tris-HCl, pH 8.0
and 500 mM KCl), 2.5 mM MgCl2 (Applied Biosystems, Man-
nheim, Germany) 200 μM dNTPs (Roche, Mannheim, Ger-
many), 11 pM of primer sets (Sigma, Taufkirchen, Germany)
and 1.5 U AmpliTaq Gold DNA-Polymerase (Applied Biosys-
tems). The sense primers were fluorescence-labeled (Hex,
FAM or TAMRA) at the 5'end. The reaction was started with
activation of the DNA polymerase for 5 min at 95°C followed
by 40 cycles of PCR amplification. To verify the microsatellite
alterations, the experiments were done as duplicates and each
PCR was repeated at least twice.
We chose the following microsatellite primers for the current
analyses: D3S1255, D9S171, D10S1765, D13S218,
D16S421, D17S250 and D17S855, because they are most
informative for the particular gene loci and binding to known
tumor-suppressor genes [12-16].
Evaluation of the data
0.5 μl of each PCR product was mixed with 40 μl HiDi Form-
amid and 0.2 μl 500-ROX size marker (Applied Biosystems,
Darmstadt, Germany), which served as an internal standard.
Each sample was denatured by heating to 94°C for 2 min.
Capillary electrophoresis analysis was performed on a
Genetic Analyzer 310 (Applied Biosystems). Samples were
injected at 15 kV for 3 s and separation was performed at 15
kV and 60°C. Data were collected with data-collection soft-
ware and analyzed by Gene-Scan 3.1 software. GeneScan-
500 standard fragments in the size range of 100 to 300 bp
were used for the calculation of relative sizes of microsatellite
alleles. The incidence of LOH was calculated by the ratio of
the intensities of the two alleles in tumor tissue, serum and BM
plasma in compared with leukocytes. LOH was interpreted if
the final quotient was < 0.6 or >1.67. Homozygous and non-
analyzable peaks were designated as non-informative cases.
Statistical analysis
The statistical analysis was performed using the SPSS soft-
ware package, version 13.0 (SPSS Inc., Chicago, Illinois,
USA). Fischer's exact test was used to identify possible asso-
ciations of the pattern of LOH with the clinical parameters,
such as tumor stage (TNM), nuclear grade, estrogene recep-
tor, progesterone receptor, HER score and the proliferation
antigen Ki-67. A value of P ≤ 0.05 was considered as statisti-
cally significant.
Results
Comparison of yields of serum DNA from BCa patients 
and healthy women
The concentration of DNA in serum of 88 BCa patients was
spectrophotometrically quantified, and revealed a range of
DNA yields between 70 and 5,000 ng/ml, with a mean value
of 500 ng/ml. There was no difference in concentrations of
serum DNA between stages M0 and M1. The range of DNA
concentrations in the 22 BM samples was between 80 and
800 ng/ml with a mean value of 310 ng/ml, and consequently
lower than the DNA levels in serum. Compared with the higher
DNA concentrations in blood and BM plasma of BCa patients,
healthy women had minor levels of DNA in their serum. The
mean value of the DNA concentrations of serum from 10 con-
trol women was 63 ng/ml. Repeated blood collections during
3 months showed a constantly low level of DNA in these sam-Breast Cancer Research    Vol 9 No 5    Schwarzenbach et al.
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ples and no occurrence of LOH on the free DNA (data not
shown).
Frequency of LOH in primary tumor, blood serum and BM 
plasma
Additional file 1 outlines the pattern of LOH detected in pri-
mary tumors, blood and BM of each BCa patient with primary
(n = 40, stage M0) and metastatic disease (n = 48, stage M1)
using a panel of 7 different polymorphic microsatellite markers.
Blood serum of the 40 M0 patients was taken after removal of
the primary tumor.' Tumor tissues and BM aspirates were avail-
able from 30 and 22 of these patients, respectively. Primary
tumors from 30 of the 48 M1 patients were obtained at the
time of primary surgery, when these patients displayed no clin-
ical signs of overt metastases (that is, 1–11 years before
blood sampling). As shown in Additional file 2, 30% of the
BCa patients (M0 and M1) harbored at least one LOH at any
of the markers tested in their blood serum. Figure 1 shows
such a LOH on free serum DNA recorded at the marker
D17S855. By contrast, 60% of the patients displayed LOH in
their primary tumor, while LOH was detected in the BM plasma
in only 18% of these patients.
The LOH index (number of LOH of each patient divided by the
informative cases) of the respective patients was higher in pri-
mary tumors (27.5%) than in serum (9.0%) and BM (5.0%)
samples. Almost half (47%) of the LOHs at any of the markers
recorded in serum could be retrieved in the corresponding pri-
mary tumors. The detected LOHs in BM could be recovered in
40% and 20% of the matched tumor and blood samples,
respectively. Among the informative cases, the frequency of
LOH in the tumors was highest for the markers D13S218
(38.0%), D17S855 (36.0%) and D17S250 (33.5%) (Figure
2a). The marker D3S1255 was the predominantly affected
region in M0 (19%) and M1 (24%) blood serum, as well as in
BM plasma (19%), indicating the same incidence of LOH on
serum and BM DNA from M0 patients and a similar rate in the
other clinical samples (Figure 2a,b). The high frequencies of
LOH at the markers D10S1765 (18.0%), D13S218 (38.0%),
D16S421 (29.0%), D17S250 (33.5%) and D17S855
(36.0%) found in tumors could not be retrieved in M0 serum
samples (Figure 2a). A comparison of the numbers of LOH
recorded in both sera from M0 and M1 patients in Figure 2b
shows the increase of the rate of LOH at the markers
D3S1255, D10S1765, D13S218 and D16S421 from M0 to
M1 stage. At the other markers (D9S171, D17S250 and
S17S855) the frequency of LOH was even higher in M0 than
M1 serum. The overall rate of LOH in M0 and M1 serum were
10.0% and 8.5%, respectively.
Figure 1
Example of a loss of heterozygosity (LOH) detected in blood serum  from a patient with breast cancer Example of a loss of heterozygosity (LOH) detected in blood serum 
from a patient with breast cancer. The fluorescence-labeled PCR prod-
ucts of leukocytes and serum DNA were separated by capillary gel 
electrophoresis on a Genetic Analyzer and evaluated with the Gene 
Scan Analysis program. The abscissa indicates the length of the PCR 
product, while the ordinate gives information on the fluorescence inten-
sity represented as peaks. The upper and lower diagram show the leu-
kocyte DNA (reference) and serum DNA amplified with the primer 
binding at the D17S855. The PCR product of the serum DNA shows a 
LOH.
Figure 2
Comparison of the frequency of loss of heterozygosity (LOH) at seven  different polymorphic microsatellite markers detected in tumor tissues,  blood and bone marrow samples from patients with primary (M0) and  metastatic (M1) breast cancer Comparison of the frequency of loss of heterozygosity (LOH) at seven 
different polymorphic microsatellite markers detected in tumor tissues, 
blood and bone marrow samples from patients with primary (M0) and 
metastatic (M1) breast cancer. The frequency of LOH was calculated 
by division of the number of LOHs with the informative cases for each 
locus.Available online http://breast-cancer-research.com/content/9/5/R66
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LOH profiles in serial serum samples during the course 
of adjuvant chemotherapy and treatment
To obtain information on the frequency of LOH during the
course of adjuvant chemotherapy and treatment, serial exami-
nations were performed using 1–3 repeated serum samples
from 28 BCa patients (n = 12 M0, n = 16 M1). These patients
were randomly chosen from the entire BCa patient cohort. In
general, the patterns of the repeated blood collections
showed no significant differences (Additional file 3).
Of the M0 patients, two women showed LOH in their first
serum sample that which disappeared during the adjuvant
therapy. By contrast, in serum of two further M0 patients with
an initial LOH-negative result, LOH could only be observed in
the second and third serum samples (Additional file 3).
The M1 serum samples displayed more frequent LOH during
treatment than M0 serum. Whereas two women of the cohort
showed LOH in their first serum sample which disappeared
during therapy, four patients were initially LOH-negative, and
LOH was only detected during therapy in the second and/or
third serum samples (Additional file 3).
Statistical evaluations of the LOH profiles with the 
established risk parameters
To determine whether a correlation exists between clinical
parameters of the BCa patients and LOHs detected at the dif-
ferent microsatellite markers, we compared tumor size (T1, T2,
T3/4), nuclear grade (G1, G2, G3), axillary lymph node status
(positive/negative), estrogen receptor (positive/negative), pro-
gesterone receptor (positive/negative), the proliferation
antigen Ki-67 (low ≤30%/high > 30%) and HER2 expression
(positive/negative) with the occurrence of LOH in the different
clinical samples. In Additional file 4, the statistically significant
associations of LOH profiles detected in primary tumors and
blood serum samples with the clinical data are summarized. In
the tumor samples, several significant correlations could be
detected. The occurrence of LOH at three markers
(D3S1255, D9S171 and D17S855) was significantly associ-
ated with higher nuclear grade of tumors. At the marker
D17S250 LOH was associated with negative estrogen and
progesterone receptor status and the high expression of the
proliferation antigen Ki-67. Besides its association with the
nuclear grade, the marker D9S171 also showed a correlation
with the antigen Ki-67 (Additional file 4). Interestingly, in M0
blood serum samples a correlation of LOH at the locus
D3S1255 to positive axillary lymph node status was observed
(Additional file 4, P = 0.05). Only M0 patients with a positive
lymph node status harbored LOHs at this marker. Also, both
M0 and M1 blood serum samples together showed a signifi-
cant correlation of positive axillary lymph node status to LOH
at this marker (Additional file 4, P = 0.004).
A statistical evaluation of the BM samples was not performed
because of the small number of BM samples (n = 22) and the
modest percentage of LOH detected in these samples (5%).
Discussion
Our present microstallite study describes the detection of free
tumor-associated DNA in blood serum and BM plasma of BCa
patients with primary and metastatic disease, and the compar-
ison of the obtained data with the LOH profiles analyzed in the
matched primary tumors. In contrast to most recent publica-
tions that apply a similar molecular approach but only examine
single compartments, we compared the coincidence of LOH
in different tissues. Our panel of seven polymorphic microsat-
ellite markers showed a higher LOH index in primary tumors
than in serum and BM samples. The implication of our finding
indicates that apart from free tumor-associated DNA blood of
BCa patients may also contain normal DNA. The prevalence of
normal DNA and the large dilution of free tumor DNA by nor-
mal DNA may hamper detection of genetic alterations in blood
as discussed by several laboratories for other tumor entities
[29-32]. However, the rates of LOH detected in these speci-
mens are similar to the range seen in other studies [11,14,15].
Surprisingly, when we compared the rate of LOH in blood from
BCa patients with primary and metastatic disease, we noticed
a higher frequency of LOH in blood derived from M0 patients
than in blood from M1 patients, suggesting that DNA loss may
contribute to early breast tumorigenesis. Another reason for
the lower incidence of LOH in M1 serum could be that meta-
static patients received treatment. In addition, the elimination
of the primary tumor may lead to the clearance of tumor-asso-
ciated DNA. Moreover, the detection of tumor-associated
DNA in blood from M0 patients after the removal of their pri-
mary tumor and also during the course of adjuvant treatment
may be explained by the persistence of tumor cells also
observed in blood and BM [33,34]. In line with this observa-
tion, the presence of LOH was not associated with tumor size,
indicating that factors other than the tumor load influence the
presence of such DNA in serum. The fact that free tumor DNA
still circulates in M1 blood sustains the theory that tumor DNA
is not only a signature of apoptotic or necrotic cells from the
primary tumor, but also of those from metastatic sources [35].
The combination of free tumor DNA from different sources
therefore makes blood an opportune clinical material for the
analysis of LOH.
With the exception of the polymorphic marker D3S1255, we
could observe a heterogeneous distribution of LOH in primary
tumor, serum and BM plasma. The pattern of LOH at the
marker D13S1255 was relatively uniform in tumor tissue,
serum and BM samples. By contrast, the lack of reflection of
the genetic patterns at the other markers in the primary tumor,
M0 blood and BM may correspond to the known multifocal
heterogeneity of these tumors. Furthermore, the possible inte-
gration of tumor DNA derived from micrometastatic cellsBreast Cancer Research    Vol 9 No 5    Schwarzenbach et al.
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should also be considered [22]. The discordant profiles of
LOH in the primary tumor and M1 blood could be due to the
different intervals between the sampling of serum from M1
patients and surgery of the primary tumor, and possibly tumor
DNA released from metastasis [36]. Furthermore, the micros-
atellite markers seem to be limited by their sensitivity in serum
or plasma. The use of SNP (single nucleotide polymorphism)
markers that only differ from each other at a single nucleotide
has recently been described to provide reliable and high qual-
ity data on a range of different DNA templates and to display
a higher sensitivity than the classical microsatellite markers
that exhibit length polymorphism. Further studies will be
required to investigate whether LOH at SNP markers are more
easily detectable in blood than LOH at microsatellite markers
[37,38].
A number of previous studies have addressed LOH mapping
in the blood or BM plasma of breast cancer patients, and have
shown the prognostic importance of circulating microsatellite
markers [20,23,39]. In addition, there are several publications
describing infrequent occurrence and non-concordance of
LOH in blood to the paired tumors [22,29-32]. To begin to
clarify these discrepancies we additionally determined the pro-
file of LOH during a follow-up study. The overall pattern of the
serial serum DNA samples was largely consistent. Whether
the detected non-concordant results are due to a changed
clinical status is unclear. Also, we cannot rule out the possibil-
ity of a shift of the relative proportions between tumor-specific
and normal DNA.
The occurrence of LOH at the marker D3S1255 in the serum
of lymph-node-positive M0 patients but not in lymph-node-
negative patients in our BCa cohort suggests that such a
blood test may reflect tumor spread. An extended and com-
bined selection of microsatellite markers could provide a bet-
ter understanding of tumor progression in breast cancer and
might facilitate the identification of high-risk breast cancer
patients. Furthermore, the development of refined techniques
for the extraction of free tumor DNA excluding particularly the
proportion of normal DNA might advance the detection of
LOH in blood. The significant association of the profile of LOH
at the marker D3S1255 to the axillary lymph node status
recorded in M0 and M0+M1 serum samples could not be
detected in the tumor tissues. However, to obtain an accurate
profile of genetic alterations in tumor tissues, the heterogene-
ity of breast tumors requires demanding analyses of several
areas of the microdissected tissues. So far, there is little infor-
mation on the microsatellite marker D3S1255 in the literature.
The marker maps to the chromosomal locus 3p23 and
encodes for arrhythmogenic right ventricular dysplasia 5
(ARVD5). A prognostic significance of LOH at 3p23 for
patients with colorectal carcinoma has been reported [40]. In
squamous cell carcinoma of the oral cavity and ovarian cancer,
frequent DNA losses were observed at this region [41,42].
Our statistical evaluation of the data obtained from the primary
tumors show significant associations between DNA deletions
at several markers and the clinopathological parameters. Con-
versely, these significances could not be found in blood
derived from M0 patients. We detected that the markers
D3S1255, D9S171 and D17S855 significantly correlated
with the nuclear grade of tumor cells. The frequent allele
losses at the marker D9S171, which is located in the vicinity
of the CDKN2 gene, whose gene product is a negative regu-
lator of the cell cycle, was suggested to be involved in the
pathogenesis of sporadic breast cancer [43]. The frequency
of LOH at D9S171 was associated with the development of
gastric cancer [44]. Concomitant losses of the BRCA1
region, which is located at the marker D17S855 together with
the BRCA2 region were significantly related to the histological
grade of the tumor [45]. Moreover, our current results denote
a significant correlation of the marker D17S250, which is
localized centromeric to BRCA1 gene, with the estrogen and
progesterone content and the proliferation marker Ki-67. A
highly significant correlation of the marker D17S250 with pos-
itive progesterone receptor status has been reported [46].
These significances only detected in primary tumors may be
masked by the prevalence of normal DNA in blood.
Conclusion
The significant associations of LOH with some risk factors and
the demonstrated possibility to monitor free DNA in patients
undergoing systemic therapy suggest that LOH analysis may
be developed into a useful diagnostic tool. However, the low
rate of LOH recorded in blood, the lack of concordance of the
LOH patterns in the different tissues, and the small and coin-
cidentally created set of microsatellite markers indicate that
the method needs to be further improved. Therefore, refine-
ment of the DNA extraction method to remove any excess of
normal DNA that might conceal the tumor DNA should be
aspired to. Examinations of larger and combined panels of dif-
ferent microsatellite markers in a multiplex PCR might improve
the identification of DNA abnormalities, providing further
insights into the complex pathogenesis of BCa.
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